Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
Donald B. Kohn, MD, of the University of California, Los Angeles, discusses hematopoietic stem cell gene therapy for primary immune deficiencies. Up to 89% of patients receiving hematopoietic…
Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination…
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel…
A recent study published in Cell Communication and Signaling presents evidence that cancer treatments that utilize adenoviruses for targeted treatment delivery may trigger additional glioma stem cell formation…
Alessia Cavazza, PhD, of Great Ormond Street Institute of Child Health (ICH) at University College London, discusses her research related to the potential of emerging gene-editing technologies, particularly…
The National Cancer Institute has developed a cloud-based infrastructure, the Cancer Research Data Commons, which allows cancer researchers to access, share, and analyze data from a centralized location,…
